Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Analysts Try To See Beyond Acadia's Alzheimer's Disease Psychosis

HC Wainwright says that a negative AdCom vote on Acadia Pharmaceuticals Inc's (NASDAQ:ACAD) perhaps marks the end of the Alzheimer's disease psychosis (ADP) story for now. 

However, looking beyond the ADP, the analysts think Acadia's pipeline still has possibilities in new indications like the Rett syndrome and for the label expansion of pimavanserin for the negative symptoms of schizophrenia.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.